Cargando…
Four cycles of adriamycin and cyclophosphamide followed by four cycles of docetaxel (NSABP-B27) with concomitant trastuzumab as neoadjuvant therapy for high-risk, early-stage, HER2-positive breast cancer patients
BACKGROUND: The majority of breast cancer patients in Jordan are diagnosed at a young age and present with metastatic or locally advanced disease. The National Surgical Adjuvant Breast and Bowel Project Protocol B27 (NSABP-B27) (four cycles of adriamycin and cyclophosphamide [AC] followed by four cy...
Autores principales: | Abdel-Razeq, Hikmat, Saadeh, Salwa S, Abu-Nasser, Mahmoud, Abdulelah, Hazem, Marie, Lina, Salam, Murad, Ali, Basel Al-Haj, Ibrahim, Mohammad, Rimawi, Dalia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905529/ https://www.ncbi.nlm.nih.gov/pubmed/29695917 http://dx.doi.org/10.2147/OTT.S151821 |
Ejemplares similares
-
Randomized phase III trial of a neoadjuvant regimen of four cycles of adriamycin plus cyclophosphamide followed by four cycles of docetaxel (AC4-D4) versus a shorter treatment of three cycles of FEC followed by three cycles of docetaxel (FEC3-D3) in node-positive breast cancer (Neo-shorter; NCT02001506)
por: Hwang, Inhwan, et al.
Publicado: (2023) -
Four cycles of docetaxel and cyclophosphamide as adjuvant chemotherapy in node negative breast cancer: A real-world study
por: Batra, Atul, et al.
Publicado: (2020) -
Comparison of neoadjuvant adriamycin and docetaxel versus adriamycin, cyclophosphamide followed by paclitaxel in patients with operable breast cancer
por: Hong, Woo Sung, et al.
Publicado: (2013) -
Treatment of anemia in cancer patients undergoing chemotherapy with
intravenous ferric carboxymaltose without erythropoiesis-stimulating
agents
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2020) -
Adriamycin/cyclophosphamide and adriamycin/melphalan in advanced L1210 leukaemia.
por: Tobias, J. S., et al.
Publicado: (1975)